Merck's COVID Pill Might Impair Natural Immune Response

Concerns over molnupiravir 

There is a recent article from ZeroHedge about molnupiravir (India Won’t Add Merck’s COVID-19 Pill To National Treatment Protocol, Citing Safety Concerns | ZeroHedge ). Molnupiravir is converted in the liver to a cytosine analog, which then becomes inserted into RNA. 

Cytosine is one of the 4 bases in RNA and DNA. Introducing an analog means that there can be mutations incorporated into the RNA strand as it is replicated. 

This is (the) strategy of using it – it will introduce mutations into the replicating viral RNA of Covid-19, thereby causing the genes to be essentially inactivated/nonfunctional. 

This is the ‘”error catastrophe” model mentioned in references cited by this review (Molnupiravir in COVID-19: 

A systematic review of literature (doi: 10.1016/j.dsx.2021.102329) This would be fine if this only affected the virus. However, this analog can be inserted into the host cell DNA. Now, our cells have the ability to repair DNA, and it is fairly robust. 

However, it has been shown that the spike protein itself has the ability to inhibit this repair process. (Jiang, H.; Mei, Y.-F. SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro. Viruses 2021, 13, 2056. https://doi.org/10.3390/ v13102056). 

But that’s not all! 

The same article suggests that the spike protein also could inhibit adaptive immunity by impairing the V(D)J recombination. 

What does that mean in English? 

It means that your cells that generate antibodies in response to the virus, are impaired from generating antibodies by the very spike protein encoded in the mRNA in the (mRNA vaccine) injections.

GO READ THE WHOLE THING.